复星医药(600196.SH)：丁二酸复瑞替尼胶囊药品注册申请获受理

Core Viewpoint - Fosun Pharma's subsidiary, Fosun Wanbang, has submitted a drug registration application for a new drug, SAF-189, which targets ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) patients, and the application has been accepted by the National Medical Products Administration [1] Group 1 - The new drug, SAF-189, is classified as a Class 1 chemical drug and is an innovative small molecule chemical drug [1] - In addition to the current application, another indication for SAF-189, targeting ROS1-positive non-small cell lung cancer, has completed Phase II clinical trials in mainland China as of January 8, 2026 [1]